BMS has welcomed the recently announced listing of immunotherapy combination OPDIVO (nivolumab) in combination with YERVOY (ipilimumab) for the treatment of advanced renal cell carcinoma. …
Latest Video
New Stories
-
New report highlights growing gene and cell therapy industry
January 24, 2020 - - Latest News -
Australian access behind comparable countries?
January 24, 2020 - - Latest News -
CSL Behring welcomes new presentations for genetic condition
January 24, 2020 - - Latest News -
Couple call on Jacinda Ardern to act on PHARMAC
January 24, 2020 - - Latest News -
Transparency of process is more important than transparency of outcome
January 23, 2020 - - Latest News -
CSL makes US-list of Best Employers for Diversity
January 23, 2020 - - Latest News -
AbbVie welcomes RINVOQ approval
January 23, 2020 - - Latest News